Reports
Sale
Global Gastrointestinal OTC Drugs Market Size, Share, Trends: By Class: Antacids, Anti-Diarrheal, Anti-Emetics, Laxatives, Others; By Indication: Heartburn, Diarrhea, Constipation, Gastroesophageal Reflux Disease, Others; By End User: Hospitals, Clinics, Home Healthcare, Others; Regional Analysis; Patent Analysis; Supplier Landscape; 2024-2032
Global Gastrointestinal OTC Drugs Market Outlook
The global gastrointestinal OTC drugs market size was valued at USD 41.96 billion in 2023, driven by the increasing awareness of gastrointestinal diseases among people across the globe. The market size is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 to achieve a value of USD 64.5 billion by 2032.
Gastrointestinal OTC Drugs: Introduction
Gastrointestinal diseases impact the entire gastrointestinal (GI) tract, spanning from the mouth to the anus. The prevalent GI disorders include irritable bowel syndrome (IBS), acid reflux, indigestion, colon cancer, and hemorrhoids, each of these conditions affect different parts of the digestive passage. The GI tract plays a crucial role in digestion, breaking down food, and facilitating nutrient absorption to maintain overall health. However, numerous GI diseases disrupt this process, interfering with the body's ability to effectively digest consumed food, potentially leading to various health complications.
To address these conditions, there are medications specifically designed for managing GI disorders, available both by prescription and over the counter. These over-the-counter gastrointestinal drugs (GI OTC drugs) aim to alleviate symptoms and manage the discomfort associated with these conditions, providing relief and support for individuals dealing with gastrointestinal issues.
Global Gastrointestinal OTC Drugs Market Analysis
The market is witnessing significant growth driven by various factors and recent advancements. Clinical trials play a pivotal role in uncovering new therapies and diagnostic tools to handle a wide range of gastrointestinal (GI) disorders, showcasing the constant evolution in treatment methodologies, further driving the market growth. The market growth is further influenced by the increasing comprehension and the number of FDA approvals exemplified by the FDA's recent approval of ‘Upadacitinib’ for treating moderately to severely active Crohn's disease. This FDA approval has marked an important milestone, following successful trials assessing its efficacy and safety, further bolstering the gastrointestinal OTC drugs market growth.
Continuous research efforts have also emphasized the importance of targeted strategies for treating gastroesophageal reflux disease (GERD) and preventing potential long-term complications. Interventional endoscopy, showing promising potential, is anticipated to shape the forecast period for GERD management as well.
Moreover, ongoing developments in the pharmaceutical sector are evident in contributing to the market growth. For instance, the New Drug Application (NDA) for Vonoprazan, the Phase 3 study of this drug showcased its efficacy and safety as a daily treatment for Non-Erosive GERD in adults. This investigational potassium-competitive acid blocker (PCAB) represents a novel class of medicines targeting acid secretion in the stomach, highlighting the dedicated interest in innovative solutions among the researchers, and contributing significantly to the growing gastrointestinal OTC drugs market share.
The combination of targeted therapies, microbiome research, and novel pharmaceutical submissions underscores a dynamic shift in GI disorder treatments, driving the growth of the global GI OTC drugs market. These advancements substantially expand treatment options coupled with a broader understanding and approach toward managing gastrointestinal conditions.
Global Gastrointestinal OTC Drugs Market Segmentations
Market Breakup by Class
- Antacids
- Laxatives
- Anti-Diarrheal
- Anti-Emetics
- Others
Market Breakup by Indication
- Heartburn
- Diarrhea
- Constipation
- Gastroesophageal Reflux Disease
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Home Healthcare
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Gastrointestinal OTC Drugs Market Overview
The market has been witnessing robust growth driven by several key factors such as the escalating incidence of gastrointestinal issues among people worldwide. This surge in prevalence increases the demand and need for over-the-counter OTC drugs, valued for their cost-effectiveness and easy accessibility. Gastrointestinal therapeutics are further benefiting from ongoing research and development innovations, fostering the development of advanced drugs, and thereby escalating the gastrointestinal OTC drugs market demand. Moreover, the burgeoning trend of self-diagnosis and self-medication is contributing to the demand for these OTC remedies.
Based on regions, North America is currently dominating the gastrointestinal OTC drugs market and is expected to continue dominating the market in the forecast period as well. The growth of the regional market is expected to be driven by the presence of robust healthcare infrastructure and favourable reimbursement policies. The region's high healthcare expenditure highlights its dominance in the global market for gastrointestinal OTC drugs.
Global Gastrointestinal OTC Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Mylan N.V.
- Sandoz AG
- Johnson & Johnson Services
- Sun Pharmaceuticals Industries
- Teva Pharmaceuticals Industries
- Zydus Cadila
- Sanofi
- Bayer AG
- Pfizer Inc.
- Amneal Pharmaceutical Inc.
- Procter & Gamble
- Hikma Pharmaceutical PLC
- Perrigo Pharmaceutical Plc.
- Abbott
- Lupin
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Class |
|
| Breakup by Indication |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Gastrointestinal OTC Drugs Market Overview
3.1 Global Gastrointestinal OTC Drugs Market Historical Value (2017-2023)
3.2 Global Gastrointestinal OTC Drugs Market Forecast Value (2024-2032)
4 Global Gastrointestinal OTC Drugs Market Landscape
4.1 Global Gastrointestinal OTC Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Gastrointestinal OTC Drugs Market: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Gastrointestinal OTC Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Gastrointestinal OTC Drugs Market Segmentation
6.1 Global Gastrointestinal OTC Drugs Market by Class
6.1.1 Market Overview
6.1.2 Antacids
6.1.3 Anti-Diarrheal
6.1.4 Anti-Emetics
6.1.5 Laxatives
6.1.6 Others
6.2 Global Gastrointestinal OTC Drugs Market by Indication
6.2.1 Market Overview
6.2.2 Heartburn
6.2.3 Diarrhea
6.2.4 Constipation
6.2.5 Gastroesophageal Reflux Disease
6.2.6 Others
6.3 Global Gastrointestinal OTC Drugs Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Clinics
6.3.4 Home Healthcare
6.3.5 Others
6.4 Global Gastrointestinal OTC Drugs Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Gastrointestinal OTC Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Gastrointestinal OTC Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Gastrointestinal OTC Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Gastrointestinal OTC Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Gastrointestinal OTC Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Other
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Mylan N.V.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Sandoz AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Johnson & Johnson Services
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Sun Pharmaceuticals Industries
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Teva Pharmaceuticals Industries
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Zydus Cadila
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Sanofi
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Bayer AG
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Pfizer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Amneal Pharmaceutical Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Procter & Gamble
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Hikma Pharmaceutical PLC
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 Perrigo Pharmaceutical Plc.
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Abbott
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Lupin
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 41.96 billion in 2023, driven by increased availability of drugs.
The market is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 and is likely to reach a market value of USD 64.5 billion by 2032.
The market growth is driven by the rising prevalence of gastrointestinal diseases, expanding healthcare sector, rising disposable incomes, and the increased development of advanced drugs.
The rising number of clinical trials in the market acts as a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Classes of gastrointestinal OTC drugs are antacids, laxatives, anti-diarrheal, and anti-emetics, among others.
Heartburn, diarrhea, constipation, and gastroesophageal reflux diseases are the major indications that require the use of OTC drugs.
End users in the market include hospitals, clinics, and home healthcare, among others.
Key players involved in the market are Mylan N.V., Sandoz AG, Johnson & Johnson Services, Sun Pharmaceuticals Industries, Teva Pharmaceuticals Industries, Zydus Cadila, Sanofi, Bayer AG, Pfizer Inc., Amneal Pharmaceutical Inc., Procter & Gamble, Hikma Pharmaceutical PLC, Perrigo Pharmaceutical Plc., Abbott, and Lupin.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER